Company intelligence / Profile preview

Aspire Bariatrics

King of Prussia, Pennsylvania, United Statesaspirebariatrics.com ↗

Ownership: Private
Employees: ~20
Development stage: Commercial

Overview

The AspireAssist device was FDA approved in June 2016 for long-term weight reduction in obese adults. Clinical trials demonstrated significant excess weight loss compared to controls (~31.5% vs. ~9.8% at one year). The company ceased operations and withdrew the product from the market effective April 8, 2022 due to financial constraints related to COVID‑19, not safety or efficacy concerns.

Therapeutic areas: Endocrinology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

AspireAssist

Commercial

Indications: Obesity, Weight management

Partnerships

No major pharmaceutical or biotech partnerships reported; collaborated with multiple academic medical centers during clinical trials

Beyond the preview

Go deeper on Aspire Bariatrics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aspire Bariatrics.

Explore the full profile